filings.toolsMedtronic 8-K 2023-12-06
Filed 2023-12-06. 1 sections, 7K characters. Original on sec.gov · Markdown · JSON
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 6, 2023
Medtronic plc
(Exact Name of Registrant as Specified in its Charter)
| Ireland | 1-36820 | 98-1183488 | ||||||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
(Address of principal executive offices)
+353 1 438-1700
(Registrant’s telephone number, including area code)
| Not Applicable | ||
| Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
| Ordinary Shares, $0.0001 par value per share | MDT | New York Stock Exchange | ||||||
| 0.250% Senior Notes due 2025 | MDT/25 | New York Stock Exchange | ||||||
| 0.000% Senior Notes due 2025 | MDT/25A | New York Stock Exchange | ||||||
| 2.625% Senior Notes due 2025 | MDT/25B | New York Stock Exchange | ||||||
| 1.125% Senior Notes due 2027 | MDT/27 | New York Stock Exchange | ||||||
| 0.375% Senior Notes due 2028 | MDT/28 | New York Stock Exchange | ||||||
| 3.000% Senior Notes due 2028 | MDT/28A | New York Stock Exchange | ||||||
| 1.625% Senior Notes due 2031 | MDT/31 | New York Stock Exchange | ||||||
| 1.000% Senior Notes due 2031 | MDT/31A | New York Stock Exchange | ||||||
| 3.125% Senior Notes due 2031 | MDT/31B | New York Stock Exchange | ||||||
| 0.750% Senior Notes due 2032 | MDT/32 | New York Stock Exchange | ||||||
| 3.375% Senior Notes due 2034 | MDT/34 | New York Stock Exchange | ||||||
| 2.250% Senior Notes due 2039 | MDT/39A | New York Stock Exchange | ||||||
| 1.500% Senior Notes due 2039 | MDT/39B | New York Stock Exchange | ||||||
| 1.375% Senior Notes due 2040 | MDT/40A | New York Stock Exchange | ||||||
| 1.750% Senior Notes due 2049 | MDT/49 | New York Stock Exchange | ||||||
| 1.625% Senior Notes due 2050 | MDT/50 | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
On May 25, 2023, Medtronic plc (Medtronic) announced that it had entered into a set of definitive agreements (Agreements) to acquire EOFlow Co. Ltd. (EOFlow) (KOSDAQ: 294090) pursuant to a share purchase agreement, a share subscription agreement, and a public tender offer, subject to the satisfaction of the minimum tender condition and certain customary closing conditions, including receipt of required regulatory clearances. On December 6, 2023, based upon multiple breaches under the Agreements, Medtronic delivered notice to EOFlow that it had exercised its right to terminate the Agreements. Medtronic does not believe any termination fee is payable under the Agreements. The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Medtronic plc | ||||||||||||||||||||
| Date: December 6, 2023 | By | /s/ Karen L. Parkhill | ||||||||||||||||||
| Karen L. Parkhill | ||||||||||||||||||||
| Executive Vice President and Chief Financial Officer |